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Introduction. The soluble urokinase-type plasminogen activator receptor (suPAR) has been found to be elevated in primary focal
segmental glomerulosclerosis (pFSGS). However, its usefulness as a biomarker for FSGS remains controversial. We conducted a
meta-analysis aiming at investigating the signiﬁcance of suPAR in diagnosing pFSGS. Methods. Electronic databases (PubMed
and EMBASE) were searched to identify studies comparing suPAR levels in FSGS patients and controls, from the earliest
available date to May 1, 2018. A random-eﬀects model with standardized mean diﬀerence (SMD) was used for meta-analyses.
Risk of bias was assessed using the Newcastle-Ottawa quality assessment scale. Results. A total of 187 articles were screened, and
the ﬁnal analysis included 13 articles. In comparison to healthy controls, serum suPAR levels were signiﬁcantly increased in
pFSGS patients (SMD, 1.07, 95% conﬁdence interval (CI) 0.65 to 1.48; participants = 814; studies = 9, I2 = 85%). Higher suPAR
levels were also found in patients with pFSGS compared to those with minimal change disease (SMD 0.53, 95% CI 0.22 to 0.84).
Of note, such a diﬀerence was not found in pediatric groups (SMD 0.42, 95% CI -0.13 to 0.96) while it was more evidently
noted in adult patients (SMD 1.32, 95% CI 0.90 to 1.74). Serum suPAR levels did not diﬀer between pFSGS patients in
remission compared to those in active proteinuric state (SMD 0.29, 95% CI -0.30 to 0.88). Comparison with membranous
nephropathy and IgA nephropathy showed no signiﬁcant diﬀerence. Conclusions. Our meta-analysis demonstrated that, in
comparison to both healthy controls and controls with minimal change disease, suPAR levels were signiﬁcantly higher in
adult patients with pFSGS. suPAR levels did not diﬀer between pFSGS patients during the initial period of diagnosis and
those in remission.
1. Introduction
Primary focal segmental glomerulosclerosis (pFSGS) is a
leading cause of glomerulonephritis which can progress to
end-stage renal disease (ESRD). pFSGS is estimated to be
responsible for 40% of adult and 20% of pediaric cases with
nephrotic syndrome [1]. Prompt diﬀerential diagnosis of
FSGS in a proteinuric patient is therefore an important
step in the management and disease course. Eﬀorts to
discover potential novel biomarkers have been attempted
to promote early diagnosis of pFSGS.
In the pathogenesis of pFSGS, circulating factors have
been regarded as signiﬁcant because in about 40% of patients,
this disease recurs after transplantation [2, 3]. The soluble
urokinase plasminogen activator receptor (suPAR) is a pro-
tein circulating in the human blood and body ﬂuids, which
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is present at low concentration in healthy individuals and
high levels in patients with infections, chronic kidney disease
(CKD), and other inﬂammatory disorders [4]. In that, its
usefulness as a biomarker has been investigated in various
diseases, such as sepsis [5], pneumonia [6], chronic obstruc-
tive pulmonary disease (COPD) [7], and kidney diseases
including pFSGS [3, 8–10]. Regarding pFSGS, suPAR has
been proposed to be a marker for diagnosis and posttrans-
plantation recurrence [1, 11–13]. However, its signiﬁcance
and reliability as a diagnostic marker for pFSGS has later
been refuted and still remains controversial [14–16].
Hence, we conducted a meta-analysis of published stud-
ies that have measured suPAR in patients with pFSGS and
controls, in order to investigate and review the usefulness of
suPAR as a potential biomarker.
2. Methods
2.1. Literature Search and Study Selection. We performed a
PubMed and EMBASE search to identify eligible articles. A
forward search of the retrieved articles was performed, and
“Google Scholar” was also assessed to screen for nonindexed
publications. The last search in EMBASE and PubMed was
performed on May 1, 2018. The search terms included
focal segmental glomerulosclerosis OR FSGS AND soluble
urokinase-type plasminogen activator receptor OR urokinase
plasminogen OR suPAR. Records were managed by EndNote
X8.0 (Clarivate Analytics, Philadelphia, PA, United States) to
remove duplicates. Publications were screened ﬁrst by title,
second by abstract, and ﬁnally by full text, based on our eligi-
bility criteria (Figure 1).
2.2. Inclusion and Exclusion Criteria. We included cross-
sectional or longitudinal studies which compared serum
suPAR levels in patients with pFSGS and healthy controls
or non-FSGS glomerular diseases: minimal change disease
(MCD), membranous nephropathy (MN), and immuno-
globulin A nephropathy (IgAN). Studies which compared
suPAR levels of active FSGS (deﬁned as initial diagnosis
or during relapse) with FSGS during remission were also
included. We excluded studies that have measured suPAR
levels in the urine or other body ﬂuids. The exclusion cri-
teria also included review articles, case reports, and animal
experiments.
2.3. Data Extraction and Outcomes. Data extraction was
carried out as recommended by the Cochrane handbook
and included authors, year of publication, study design,
participants, demographic characteristics, histopathology,
and measurement of serum suPAR. Both review of full texts
and extraction of data were independently performed by
two reviewers (Lee JM and Yang JW). Any disagreement
between the two primary reviewers was resolved by discus-
sion with the third party (Shin JI).
Serum suPAR levels were collected as mean ± standard
deviation (SD). Where data were given in median and inter-
quartile ranges (IQR), we used the quantile method for
187 articles reviewed by title screening
126 articles were excluded
63 were duplicates
26 reviews
25 were comments
8 were animal studies
3 were cell studies
1 was a case report
42 articles were excluded
12 were abstracts of scientific meetings
5 were experimental studies
3 were not about suPAR
20 were not about pFSGS
2 were about urinary suPAR
6 articles were excluded
3 were not available for the raw data
3 had no control groups
61 articles reviewed by abstract screening
19 articles reviewed by full text screening
13 eligible articles published until May 1, 2018
Figure 1: Flow chart of literature search. ∗Abbreviations: SUPAR: soluble urokinase-type plasminogen activator receptor; pFSGS: primary
focal segmental glomerulosclerosis.
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estimating X (mean) and S (standard deviation) from mean
and IQR, proposed by Wan and colleagues [17]:
X ≈
q1 +m + q3
3 ,
S ≈
q3 − q1
1 35
1
2.4. Quality Assessment. This meta-analysis was conducted
and reported according to the PRISMA (Preferred Report-
ing Items for Systematic Reviews and Meta-Analysis)
statement (Supplementary Table S1). Risk of bias of
individual studies at the outcome level was assessed by
using the Newcastle-Ottawa Scale (NOS) (Supplementary
Table S2).
2.5. Statistical Analysis and Evaluation of Heterogeneity and
Publication Bias. In the meta-analysis, the standardized
mean diﬀerence (SMD) method and corresponding 95%
conﬁdence intervals (CIs) were used to compare suPAR
levels. Random eﬀect models were used because of heteroge-
neity of the included studies. We assessed the heterogeneity
of the studies by using the Cochran Q test, and a P value
of <0.1 was considered signiﬁcant. The inconsistency across
the studies was also measured by the I2 metric, as a measure
of the percentage of total variation across the studies because
of the heterogeneity. I2 values of <25, 25-75, and >75% were
considered to represent low, moderate, and high levels of
heterogeneity, respectively. Publication bias of each article
was estimated by inspecting the funnel plot and using the
Egger test when there were 10 or more eligible studies. All
analyses were conducted using Comprehensive Meta-
Analysis v.2.0 (Biostat, Englewood, NJ, USA) and RevMan
5.3 (The Nordic Cochrane Centre).
3. Results
3.1. Study Selection and Characteristics. A total of 187 articles
were identiﬁed using electronic and manual research. After
reviewing titles and abstracts, 19 studies were selected for
full-text reading. Of them, 6 were excluded (3 studies had
no control groups and 3 studies were not available for the
raw data) to ﬁnally include 13 eligible articles [13–15, 18–
27]. The detailed process of article selection is shown in
Figure 1. The respective characteristics of the included stud-
ies are described in detail in Table 1.
The PRISMA checklist for meta-analysis is shown in
Supplementary Table S1. The study quality assessed by
using the Newcastle-Ottawa scale (NOS) scored 6 in nine
studies and 7 in four studies (range, 1 (very poor) to 9 (very
high); Supplementary Table S2).
3.2. Meta-Analysis of suPAR Levels in pFSGS Patients
Compared to Healthy Controls. A meta-analysis on pFSGS
patients and healthy controls was performed. Among the
13 studies, there were 9 studies which examined suPAR levels
in 418 pFSGS patients and 396 healthy controls. The results
revealed that suPAR levels were signiﬁcantly higher in the
pFSGS group compared with those in the control group
(SMD 1.07, 95% CI 0.65 to 1.48; participants = 814;
studies = 9; I2 = 85%) (Table 2; Figure 2). The overall mean
concentration of serum suPAR was 4470 ± 1390 (pg/mL) in
pFSGS groups and 2399 ± 487 (pg/mL) in the control group
(Table 2). A funnel plot of standard error for this meta-
analysis did not reveal signiﬁcant publication bias (Figure 3).
3.3. Meta-Analysis of suPAR Levels in pFSGS Patients
Compared to Disease Controls. Ten studies compared suPAR
levels in 503 patients with pFSGS and 296 with MCD,
indicating signiﬁcantly higher levels in patients with pFSGS
compared to those with MCD, 3550 ± 1456 pg/mL and
2790 ± 1048 pg/mL (SMD 0.53, 95% CI 0.22 to 0.84;
participants = 952; studies = 13; I2 = 85%) (Table 2;
Figure 2). In this meta-analysis, the study by Sinha et al.
[14] was counted separately for three times because they
compared serum suPAR levels in three diﬀerent groups:
patients at active (nephrotic) state, patients in remis-
sion, and nonresponders.
Patients with pFSGS were compared with MN and
IgAN patients for their serum suPAR levels. The results
were statistically insigniﬁcant for FSGS (3604 ± 1865 pg/mL)
versus MN (3069 ± 1600 pg/mL) (SMD 0.36, 95% CI
-0.01 to 0.73; participants = 666; studies = 7) and FSGS
(3001 ± 899 pg/mL) versus IgAN (2833 ± 722 pg/mL) (SMD
0.29, 95% CI -0.30 to 0.88; participants = 199; studies = 3).
3.4. Meta-Analysis of suPAR Levels in pFSGS Patients with
and without Active Proteinuria.We compared serum suPAR
levels in pFSGS patients with active proteinuria (n = 90) and
those in remission of proteinuria (n = 62). The meta-
analysisshowed that there was a trend towards higher
suPAR levels during active disease which, however, did
not yield signiﬁcance (SMD 0.29, 95% CI -0.30 to 0.88;
participants = 199; studies = 3) (Table 2; Figure 2).
3.5. Serum suPAR Levels in Pediatric and Adult Groups. We
compared serum suPAR levels in pediatric and adult groups.
The results revealed that children with pFSGS had no signif-
icant diﬀerence in their suPAR levels compared to any con-
trols (Figure 4; Table 3). For adult patients, however, serum
suPAR levels were signiﬁcantly more elevated in pFSGS
patients compared to both healthy controls and MCD con-
trols. It showed statistically powerful results even after elim-
inating the outliers. In the comparison meta-analysis on
adults with FSGS vs. MCD (1.5.4 of Figure 4), the study by
Chen et al. [26] was counted as an outlier and not included
for the ﬁnal calculation. Basal serum levels of suPAR in both
healthy and MCD controls were higher in children than
adults (Table 3).
3.6. Assessment of Heterogeneity and Publication Bias. We
assessed statistical heterogeneity between the included
studies (Table 2). Since the I2 test showed a value > 50%,
indicating substantial heterogeneity, we used random eﬀect
models for meta-analyses. The funnel plot showed near
symmetry (Figure 2).
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4. Discussion
The usefulness of suPAR as a biomarker of FSGS has been a
controversial issue. In an in vitromodel, Alfano et al. showed
that suPAR induces downmodulation of nephrin in human
podocytes and that it may result in renal dysfunction in
diﬀerent human pathologies characterized by increased
concentration of suPAR [28]. Elevation of suPAR levels was
demonstrated in patients with pFSGS as well. Wei and
colleagues, in their comprehensive study, reported a marked
elevation of suPAR levels in two large cohorts, 84.3% (North
American) and 55.3% (the European PodoNet) of pFSGS
patients compared with 6% of controls [11]. Such an observa-
tion was consistently noted when compared to patients with
other glomerulonephritis [10, 11, 13, 15, 29]. Serum suPAR
levels correlated with proteinuria and declined estimated
Std. mean difference
IV, random, 95% Cl
-4 -2
Lower suPAR Higher suPAR
0 2 4
Experimental
Study or subgroup Mean SD
Control Std. mean difference
Mean SD IV, random, 95% CI Year
1.2.1 FSGS vs. control
Huang et al. 2013 3,162.7 1,596.3 74 1,792.7 360.74 56 13.0% 1.11 [0.74, 1.48] 2013
Bock et al. 2013 2,676.3 859.3 20 2,430 411.11 29 11.4% 0.38 [-0.19, 0.96] 2013
Franco Palacios et al. 2013 5,795.3 2,193.3 28 2,398.7 487.41 10 9.2% 1.74 [0.90, 2.57] 2013
Sinha et al. 2014 3,104.3 994.3 46 3,021.1 1,416.7 83 13.1% 0.06 [-0.30, 0.42] 2014
Li et al. 2014 3,325 1,480.7 109 1,866 480.74 96 13.5% 1.29 [0.99, 1.59] 2014
Wada et al. 2014 3,119 1,036.6 38 1,745.1 395.4 17 10.8% 1.52 [0.87, 2.16] 2014
Fujimoto et al. 2015 3,392.3 1,057 8 1,650.67 360.74 20 7.1% 2.69 [1.57, 3.80] 2015
Jin et al. 2015 5,072.7 6,233 86 2,187.33 1,545.19 69 13.3% 0.60 [0.28, 0.93] 2015
Sołtysiak et al. 2016 4,470 1,390 9 3,230 760 16 8.7% 1.17 [0.28, 2.06] 2016
Subtotal (95% CI) 418 396 100.0% 1.07 [0.65, 1.48]
Heterogeneity: tau2 = 0.31; chi2 = 52.08, df = 8 (P < 0.00001); I2 = 85%
Test for overall effect: Z = 5.01 (P < 0.00001)
1.2.2 FSGS vs. MCD
Bock et al. 2013 2,676.3 859.259 20 3,271.67 1,173.33 5 5.4% -0.62 [-1.62, 0.37] 2013
Huang et al. 2013 3,162.67 1,596.3 74 2,037.33 322.963 14 8.5% 0.76 [0.17, 1.34] 2013
Li et al. 2014 3,325 1,480.74 109 1,778.67 522.963 20 9.2% 1.11 [0.62, 1.61] 2014
Segarra et al. 2014 3,939 849 20 2,669 629 16 6.9% 1.63 [0.86, 2.40] 2014
Sinha et al. 2014_active 3,104.3 994.29 46 3,402.7 1,683.53 54 10.1% -0.21 [-0.60, 0.18] 2014
Sinha et al. 2014_nonresponder 3,695.2 1,374.73 28 2,947.3 874.511 17 8.2% 0.61 [-0.01, 1.22] 2014
Sinha et al. 2014_remission 3,309.9 1,082.39 52 3,203.6 1,176.29 71 10.4% 0.09 [-0.27, 0.45] 2014
Wada et al. 2014 3,119 1,036.6 38 2,374.9 588.8 11 7.6% 0.76 [0.07, 1.45] 2014
Jin et al. 2015 5,081.67 6,233.33 86 3,167.67 3,214.07 65 10.6% 0.37 [0.04, 0.69] 2015
Spinale et al. 2015 3,207.33 801.48 95 2,512.67 645.926 62 10.6% 0.93 [0.59, 1.27] 2015
Fujimoto et al. 2015 3,392.33 1,057.04 8 3,363.33 1,283.7 10 5.8% 0.02 [-0.91, 0.95] 2015
Sołtysiak et al. 2016 4,470 1,390 9 3,510 1,330 22 6.7% 0.69 [-0.10, 1.49] 2016
Chen et al. 2016 3,670 170 18 2,030 180 22 Not estimable 2016
Subtotal (95% CI) 585 367 100.0% 0.53 [0.22, 0.84]
Heterogeneity: tau2 = 0.21; chi2 = 46.01, df = 11 (P < 0.00001); I2 =76%
Test for overall effect: Z = 3.32 (P = 0.0009)
1.2.3 FSGS vs. MN
Huang et al. 2013 3,162.67 1,596.3 74 2,085.33 891.11 29 15.7% 0.74 [0.30, 1.19] 2013
Li et al. 2014 3,325 1,480.74 109 1,707.33 592.59 22 15.1% 1.17 [0.69, 1.65] 2014
Wada et al. 2014 3,119 1,036.6 38 3,311.9 655.3 9 11.3% -0.19 [-0.92, 0.53] 2014
Segarra et al. 2014 3,939 849 20 3,373 1,073 24 13.1% 0.57 [-0.04, 1.17] 2014
Jin et al. 2015 5,081.67 6,233.33 86 4,315.33 5,520 85 17.9% 0.13 [-0.17, 0.43] 2015
Fujimoto et al. 2015 3,392.33 1,057.04 8 3,460 1,514.07 15 9.6% -0.05 [-0.91, 0.81] 2015
Spinale et al. 2015 3,207.33 801.481 95 3,227 951.11 52 17.4% -0.02 [-0.36, 0.32] 2015
Subtotal (95% CI) 430 236 100.0% 0.36 [-0.01, 0.73]
Heterogeneity: tau2 = 0.17; chi2 = 24.32, df = 6 (P = 0.0005); I2 = 75%
Test for overall effect: Z = 1.93 (P = 0.05)
1.2.4 FSGS vs. IgAN
Bock et al. 2013 2,676.33 859.26 20 3,190 322.22 3 16.8% -0.60 [-1.83, 0.63] 2013
Wada et al. 2014 3,119 1,036.6 38 2,311.3 777.1 11 33.9% 0.81 [0.11, 1.50] 2014
Spinale et al. 2015 3,207.33 801.48 95 2,997.33 1,065.19 32 49.3% 0.24 [-0.16, 0.64] 2015
Subtotal (95% CI) 153 46 100.0% 0.29 [-0.30, 0.88]
Heterogeneity: tau2 = 0.14; chi2 = 4.21, df = 2 (P = 0.12); I2 = 52%
Test for overall effect: Z = 0.97 (P = 0.33)
1.2.5 FSGS-A vs. FSGS-R
Meijers et al. 2014 3,605.33 1,333.33 44 2,824.33 671.85 10 43.6% 0.62 [-0.08, 1.32] 2014
Sinha et al. 2014 3,104.3 994.29 46 3,309.9 1,082.39 52 56.4% -0.20 [-0.59, 0.20] 2014
Subtotal (95% CI) 90 62 100.0% 0.16 [-0.63, 0.95]
Heterogeneity: tau2 = 0.25; chi2 = 3.95, df = 1 (P = 0.05); I2 = 75%
Test for overall effect: Z = 0.39 (P = 0.69)
Test for subgroup differences: chi2 = 8.62, df = 4 (P = 0.07); I2 = 53.6%
Total Total Weight
Figure 2: Forest plot of random eﬀects meta-analysis of serum suPAR levels in FSGS patients. Squares are proportional to study weight.
∗Abbreviations: SUPAR: soluble urokinase-type plasminogen activator receptor; FSGS: focal segmental glomerulosclerosis.
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glomerular ﬁltration rate (eGFR) [11, 13]. Furthermore,
suPAR has been demonstrated to correlate with development
of recurrent FSGS after kidney transplantation (KT) [30].
However, other investigators found that serum suPAR
levels in FSGS were similar to controls and questioned its
signiﬁcance as a biomarker and that suPAR failed to discrim-
inate pFSGS from other glomerulonephritis forms such as
MCD, MN, IgAN, lupus nephritis, or nonglomerular CKD
[3, 14, 18–23, 31–34]. Moreover, elevated serum suPAR
levels have been demonstrated in patients with nonrenal
conditions, such as cancer, sepsis, systemic inﬂammatory
response syndrome (SIRS), and cardiovascular disease, and
have been shown to be associated with a poor clinical out-
come [35–37]. In addition, it has been suggested that the
inverse correlation between suPAR and eGFR may be due
to impaired renal excretion itself, rather than its function
as a biomarker [14]. The results from these studies implied
that while suPAR may indeed be increased in pFSGS, it
might be nonspeciﬁcally involved in the pathogenesis of
various diseases.
We propose the following explanations for pleiotropic
eﬀects of suPAR:
First, diﬀerent isoforms and glycosylation statuses of
suPAR may have diﬀerent impacts. suPAR is present in
variable forms from suPAR I to III. Trachtman et al. consid-
ered that it is likely that while all forms of suPAR can bind to
αvβ3 integrin which is a key modulator in the pathogenic
process in podocytes, its subsequent activation might vary
depending on the speciﬁc form of suPAR [38]. Moreover,
Maas et al. speculated that the vitronectin-binding capacity
of suPAR fragments might determine the activity as a FSGS
factor [16]. In addition, the glycosylation status of suPAR
may inﬂuence inducing proteinuria in pFSGS [39]. Since
the currently available ELISA kit can only detect glycosylated
suPAR of full length [39], characterization of the diﬀer-
ent isoforms and their biologic activity should later be
addressed [3].
Second, modifying factors may have mediated suPAR-
induced activation of αvβ3 integrin. Loss of podocyte-
protective factors or an underlying permissive genetic back-
ground has been proposed [3, 40]. Recently, SMPDL-3b
was reported as an important regulator of suPAR-induced
activation of αvβ3 integrin signaling in podocytes by Yoo
et al. [41].
Third, major confounders of suPAR need to be con-
trolled. In normal populations, higher suPAR levels were
found in women, smokers, older subjects, and African race
[3, 42, 43]. These factors are required to be matched or
adjusted when selecting healthy or disease controls. Further-
more, serum levels of inﬂammation markers (i.e., C-reactive
protein (CRP) or erythrocyte sedimentation rate (ESR))
and renal function (GFR) need to be adjusted for, as inﬂam-
mation itself can aﬀect suPAR and low GFR may amplify
suPAR levels due to impaired clearance [3].
Fourth, with regard to statistics, most of the studies
performed simple comparison analysis presenting the diﬀer-
ences in suPAR levels among groups. A more powerful study
would require performing multiple logistic regression analy-
sis to ﬁnd independent predictors and receiver operating
characteristic (ROC) curve analysis to calculate sensitivity
and speciﬁcity [3].
In the present meta-analysis, serum suPAR levels were
elevated in pFSGS patients compared to controls and this
ﬁnding was consistent when compared to MCD, but not for
MN or IgAN. We postulate that the results may still imply
a potential role of suPAR in diﬀerential diagnosis of pFSGS
from other forms of nephrotic glomerulonephritis, since
distinguishing FSGS from MCD has long been a diagnostic
challenge. However, we also noticed that serum suPAR levels
had no signiﬁcant diﬀerence in children and that we also
found that serum FSGS levels were generally elevated overall
in children than in adults. This ﬁnding may be biased due to
the absolute paucity of pediatric data or have been aﬀected by
elevated basal suPAR levels in pediatric controls. In either
case, we propose that future studies on serum suPAR should
better be age-stratiﬁed.
Moreover, the results must be interpreted with caution
for the following reasons. First, pFSGS is a heterogeneous
disorder with diverse etiopathogenesis and diﬀerent histopa-
thology. Sometimes, even misclassiﬁcation may occur since
the distinction between primary and secondary FSGS may
not always be feasible [3]. Since the etiology has a wide
spectrum, it is important to specify the subgroup of patients
in whom suPAR is the contributing circulating factor [44].
It has also been suggested that the role of suPAR should be
interpreted in the context with recurrent FSGS after KT,
which is considered to be circulating factor-mediated [3].
In short, the eﬀect of circulating factors, such as suPAR on
pFSGS, may have a diﬀerent impact depending on the etio-
pathology. Second, there is still paucity of data. The present
meta-analysis contained 13 studies and even fewer for
subgroup analysis. Further subgroup comparisons including
histopathology, gender, age, and ethnicity groups were not
available. In addition, although there were studies that
reported the correlation of serum suPAR with eGFR
[13, 14, 19, 20, 22, 27], subgroup analyses by eGFR were
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Figure 3: Funnel plot of standard error in meta-analysis of
serum suPAR levels in pFSGS patients compared with controls.
∗Abbreviations: SUPAR: soluble urokinase-type plasminogen
activator receptor; pFSGS: primary focal segmental glomerulosclerosis.
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not feasible because the data were not diﬀerentially pres-
ent according to eGFR. Further meta-analyses containing
studies with more patients would help in verifying the
results of the present study.
Our study has some limitations. There were a few (three)
studies excluded from the full-text research due to lack of
raw data. In addition, some studies did not present the
mean ± standard deviation (SD), hampering the meta-
analysis. Also, there remains the possibility of existing case
reports or series that were not accessible. In future studies, an
individual patient data meta-analysis and propensity score
matching would be powerful in investigating whether suPAR
could be a reliable surrogate biomarker of pFSGS.
Although the results require cautious interpretation,
the study provides evidence based on current publications.
The present meta-analysis showed that serum suPAR was
increased in patients with pFSGS compared to controls
and also diﬀerentially among other glomerulonephritis
Table 3: Comparison of pediatric and adult data.
Serum suPAR levels (No. of studies/No. of patients)
pFSGS Controls pFSGS MCD
Pediatric
3417 ± 1082
(3 studies, n = 75)
2894 ± 863
(3 studies, n = 128)
3451 ± 1140
(5 studies, n = 155)
3267 ± 1248
(5 studies, n = 169)
Adult
3979 ± 2266
(6 studies, n = 343)
1940 ± 605
(6 studies, n = 268)
3612 ± 1653
(8 studies, n = 448)
2492 ± 923
(8 studies, n = 220)
∗suPAR: soluble urokinase-type plasminogen activator receptor; pFSGS: primary focal segmental glomerulosclerosis; MCD: minimal change disease.
Experimental
Study or subgroup Mean SD Total
Control Std. mean difference
Mean SD Total Weight YearIV, random, 95% CI
Std. mean difference
IV, random, 95% CI
1.5.1 Children: FSGS vs. control
Bock et al. 2013 2,676.3 859.3 20 2,430 411.11 29 4.9% 0.38 [-0.19, 0.96] 2013
Sinha et al. 2014 3,104.3 994.3 46 3,021.1 1,416.7 83 5.6% 0.06 [-0.30, 0.42] 2014
Sołtysiak et al. 2016 4,470 1,390 9 3,230 760 16 3.9% 1.17 [0.28, 2.06] 2016
Subtotal (95% CI) 75 128 14.4% 0.42 [-0.13, 0.96]
Heterogeneity: tau2 = 0.14; chi2 = 5.33, df = 2 (P = 0.07); I2 = 62%
Test for overall effect: Z = 1.51 (P = 0.13)
1.5.2 Adult: FSGS vs. control
Franco Palacios et al. 2013 5,795.3 2,193.3 28 2,398.7 487.41 10 4.1% 1.74 [0.90, 2.57] 2013
Huang et al. 2013 3,162.7 1,596.3 74 1,792.7 360.74 56 5.6% 1.11 [0.74, 1.48] 2013
Wada et al. 2014 3,119 1,036.6 38 1,745.1 395.4 17 4.7% 1.52 [0.87, 2.16] 2014
Li et al.2014 3,325 1,480.7 109 1,866 480.74 96 5.7% 1.29 [0.99, 1.59] 2014
Fujimoto et al. 2015 3,392.3 1,057 8 1,650.67 360.74 20 3.2% 2.69 [1.57, 3.80] 2015
Jin et al. 2015 5,081.7 6,233.3 86 2,187.33 1,545.19 69 5.7% 0.61 [0.28, 0.93] 2015
Subtotal (95% CI) 343 268 28.9% 1.32 [0.90, 1.74]
Heterogeneity: tau2 = 0.18; chi2 = 22.01, df = 5 (P = 0.0005); I2 = 77%
Test for overall effect: Z = 6.22 (P < 0.00001)
1.5.3 Children: FSGS vs. MCD
Bock et al. 2013 2,676.3 859.259 20 3,271.67 1,173.33 5 3.5% -0.62 [-1.62, 0.37] 2013
Sinha et al. 2014_active 3,104.3 994.29 46 3,402.7 1,683.53 54 5.5% -0.21 [-0.60, 0.18] 2014
Sinha et al. 2014_nonresponder 3,695.2 1,374.73 28 247.3 874 17 4.0% 2.79 [1.94, 3.65] 2014
Sinha et al. 2014_remission 3,309.9 1,082.39 52 3,203.6 1,176.29 71 5.6% 0.09 [-0.27, 0.45] 2014
Sołtysiak et al. 2016 4,470 1,390 9 3,510 1,330 22 4.2% 0.69 [-0.10, 1.49] 2016
Subtotal (95% CI) 155 169 22.8% 0.52 [-0.34, 1.39]
Heterogeneity: tau2 = 0.85; chi2 = 44.07, df = 4 (P < 0.00001); I2 = 91%
Test for overall effect: Z = 1.18 (P = 0.24)
1.5.4 Adult: FSGS vs. MCD
Huang et al. 2013 3,162.67 1,596.3 74 2,037.33 322.963 14 4.9% 0.76 [0.17, 1.34] 2013
Li et al. 2014 3,119 1,036.6 38 2,374.9 588.8 11 4.5% 0.76 [0.07, 1.45] 2014
Wada et al. 2014 3,325 1,480.74 109 1,778.67 522.963 20 5.2% 1.11 [0.62, 1.61] 2014
Segarra et al. 2014 3,939 849 20 2,669 629 16 4.3% 1.63 [0.86, 2.40] 2014
Spinale et al. 2015 3,392.33 1,057.04 8 3,363.33 1,283.7 10
3.7%
0.02 [-0.91, 0.95] 2015
Fujimoto et al. 2015 3,207.33 801.48 95 2,512.67 645.926 62
5.7%
0.93 [0.59, 1.27] 2015
Jin et al. 2015 5,081.67 6,233.33 86 3,167.67 3,214.07 65
5.7%
0.37 [0.04, 0.69] 2015
Chen et al. 2016 3,670 170 18 2,030 180 22 Not estimable 2016
Subtotal (95% CI) 430 198 33.9% 0.80 [0.48, 1.13]
Heterogeneity: tau2 = 0.11; chi2 = 15.84, df = 6 (P = 0.01); I2 = 62%
Test for overall effect: Z = 4.85 (P < 0.00001)
Total (95% CI) 1003 763 100.0% 0.85 [0.56, 1.14]
Heterogeneity: tau2 = 0.35; chi2 = 135.55, df = 20 (P < 0.00001); I2 = 85%
Test for overall effect: Z = 5.79 (P < 0.00001)
Test for subgroup differences: chi2 = 7.94, df = 3 (P = 0.05), I2 = 62.2%
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Figure 4: Forest plot of meta-analysis of serum suPAR levels compared in children and adult groups. ∗Abbreviations: SUPAR: soluble
urokinase-type plasminogen activator receptor; pFSGS: primary focal segmental glomerulosclerosis; MCD minimal change disease.
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forms. suPAR levels did not diﬀer between pFSGS patients
with active disease and those in remission. Further studies
are needed to investigate its clinical usefulness as a
biomarker.
Data Availability
The raw data supporting this meta-analysis are from
previously reported studies and datasets, which have been
cited. The processed data are included within the article.
The full processed data in detail are also available from the
corresponding author upon request.
Conflicts of Interest
All of the authors declare no competing interest.
Authors’ Contributions
Jiwon M. Lee and Jae Won Yang contributed equally to
this work.
Acknowledgments
This study was supported by Chungnam National University
Hospital Research Fund, 2017.
Supplementary Materials
Table S1: PRISMA 2009 checklist. Table S2: the
Newcastle-Ottawa Scale (NOS). (Supplementary Materials)
References
[1] B. Sprangers, B. Meijers, and G. Appel, “FSGS: diagnosis
and diagnostic work-up,” BioMed Research International,
vol. 2016, Article ID 4632768, 8 pages, 2016.
[2] A. Kronbichler, J. Oh, B. Meijers, and J. I. Shin, “Focal
segmental glomerulosclerosis: genetics, mechanism, and
therapies,” BioMed Research International, vol. 2016, Article
ID 9643785, 2 pages, 2016.
[3] A. Kronbichler, M. A. Saleem, B. Meijers, and J. I. Shin, “Solu-
ble urokinase receptors in focal segmental glomerulosclerosis:
a review on the scientiﬁc point of view,” Journal of Immunol-
ogy Research, vol. 2016, Article ID 2068691, 14 pages, 2016.
[4] R. N. Wlazeł, I. Szadkowska, P. Bartnicki, K. Rośniak-Bąk, and
J. Rysz, “Clinical and prognostic usefulness of soluble uroki-
nase plasminogen activator receptor in hemodialysis patients,”
International Urology and Nephrology, vol. 50, no. 2, pp. 339–
345, 2018.
[5] J. J. Zhao, X. L. Lou, H. W. Chen, F. T. Zhu, and Y. Q. Hou,
“Diagnostic value of decoy receptor 3 combined with procalci-
tonin and soluble urokinase-type plasminogen activator recep-
tor for sepsis,” Cellular & Molecular Biology Letters, vol. 23,
no. 1, p. 22, 2018.
[6] Q. Luo, P. Ning, Y. Zheng, Y. Shang, B. Zhou, and Z. Gao,
“Serum suPAR and syndecan-4 levels predict severity of
community-acquired pneumonia: a prospective, multi-centre
study,” Critical Care, vol. 22, no. 1, p. 15, 2018.
[7] N. S. Godtfredsen, D. V. Jørgensen, K. Marsaa et al., “Soluble
urokinase plasminogen activator receptor predicts mortality
in exacerbated COPD,” Respiratory Research, vol. 19, no. 1,
p. 97, 2018.
[8] S. S. Hayek, S. Sever, Y. A. Ko et al., “Soluble urokinase recep-
tor and chronic kidney disease,” The New England Journal of
Medicine, vol. 373, no. 20, pp. 1916–1925, 2015.
[9] M. Zeier and J. Reiser, “suPAR and chronic kidney disease—a
podocyte story,” Pﬂügers Archiv - European Journal of Physiol-
ogy, vol. 469, no. 7-8, pp. 1017–1020, 2017.
[10] G. Cara-Fuentes, C. Wei, A. Segarra et al., “CD80 and suPAR
in patients with minimal change disease and focal segmental
glomerulosclerosis: diagnostic and pathogenic signiﬁcance,”
Pediatric Nephrology, vol. 29, no. 8, pp. 1363–1371, 2014.
[11] C. Wei, H. Trachtman, J. Li et al., “Circulating suPAR in two
cohorts of primary FSGS,” Journal of the American Society of
Nephrology, vol. 23, no. 12, pp. 2051–2059, 2012.
[12] C. Wei, C. C. Möller, M. M. Altintas et al., “Modiﬁcation of
kidney barrier function by the urokinase receptor,” Nature
Medicine, vol. 14, no. 1, pp. 55–63, 2008.
[13] F. Li, C. Zheng, Y. Zhong et al., “Relationship between serum
soluble urokinase plasminogen activator receptor level and ste-
roid responsiveness in FSGS,” Clinical Journal of the American
Society of Nephrology, vol. 9, no. 11, pp. 1903–1911, 2014.
[14] A. Sinha, J. Bajpai, S. Saini et al., “Serum-soluble urokinase
receptor levels do not distinguish focal segmental glomer-
ulosclerosis from other causes of nephrotic syndrome in
children,” Kidney International, vol. 85, no. 3, pp. 649–
658, 2014.
[15] J. Huang, G. Liu, Y. M. Zhang et al., “Plasma soluble urokinase
receptor levels are increased but do not distinguish primary
from secondary focal segmental glomerulosclerosis,” Kidney
International, vol. 84, no. 2, pp. 366–372, 2013.
[16] R. J. Maas, J. K. Deegens, and J. F. Wetzels, “Serum suPAR in
patients with FSGS: trash or treasure?,” Pediatric Nephrology,
vol. 28, no. 7, pp. 1041–1048, 2013.
[17] X. Wan, W.Wang, J. Liu, and T. Tong, “Estimating the sample
mean and standard deviation from the sample size, median,
range and/or interquartile range,” BMC Medical Research
Methodology, vol. 14, no. 1, p. 135, 2014.
[18] M. E. Bock, H. E. Price, L. Gallon, and C. B. Langman, “Serum
soluble urokinase-type plasminogen activator receptor levels
and idiopathic FSGS in children: a single-center report,” Clin-
ical Journal of the American Society of Nephrology, vol. 8, no. 8,
pp. 1304–1311, 2013.
[19] C. R. Franco Palacios, J. C. Lieske, H. M. Wadei et al., “Urine
but not serum soluble urokinase receptor (suPAR) may iden-
tify cases of recurrent FSGS in kidney transplant candidates,”
Transplantation, vol. 96, no. 4, pp. 394–399, 2013.
[20] T. Wada, M. Nangaku, S. Maruyama et al., “A multicenter
cross-sectional study of circulating soluble urokinase receptor
in Japanese patients with glomerular disease,” Kidney Interna-
tional, vol. 85, no. 3, pp. 641–648, 2014.
[21] B. Meijers, R. J. H. Maas, B. Sprangers et al., “The soluble
urokinase receptor is not a clinical marker for focal segmental
glomerulosclerosis,” Kidney International, vol. 85, no. 3,
pp. 636–640, 2014.
[22] A. Segarra, E. Jatem, M. T. Quiles et al., “Diagnostic value of
soluble urokinase-type plasminogen activator receptor serum
levels in adults with idiopathic nephrotic syndrome,” Nefrolo-
gía, vol. 34, no. 1, pp. 46–52, 2014.
[23] J. M. Spinale, L. H. Mariani, S. Kapoor et al., “A reassessment
of soluble urokinase-type plasminogen activator receptor in
10 Journal of Immunology Research
glomerular disease,” Kidney International, vol. 87, no. 3,
pp. 564–574, 2015.
[24] K. Fujimoto, J. Imura, H. Atsumi et al., “Clinical signiﬁcance of
serum and urinary soluble urokinase receptor (suPAR) in
primary nephrotic syndrome and MPO-ANCA-associated
glomerulonephritis in Japanese,” Clinical and Experimental
Nephrology, vol. 19, no. 5, pp. 804–814, 2015.
[25] J. Jin, Y. W. Li, and Q. He, “Primary and recurrent focal
segmental glomerulosclerosis closely link to serum soluble
urokinase-type plasminogen activator receptor levels,”
Transplantation Proceedings, vol. 47, no. 6, pp. 1760–
1765, 2015.
[26] J. S. Chen, L. C. Chang, C. Z. Wu et al., “Signiﬁcance of the
urokinase-type plasminogen activator and its receptor in the
progression of focal segmental glomerulosclerosis in clinical
and mouse models,” Journal of Biomedical Science, vol. 23,
no. 1, p. 24, 2016.
[27] J. Sołtysiak, J. Zachwieja, A. Benedyk, M. Lewandowska-
Stachowiak, M. Nowicki, and D. Ostalska-Nowicka, “Circulat-
ing suPAR as a biomarker of disease severity in children with
proteinuric glomerulonephritis,” Minerva Pediatrica, vol. 71,
no. 1, pp. 4–11, 2016.
[28] M. Alfano, P. Cinque, G. Giusti et al., “Full-length soluble
urokinase plasminogen activator receptor down-modulates
nephrin expression in podocytes,” Scientiﬁc Reports, vol. 5,
no. 1, article 13647, 2015.
[29] C. Wei, S. el Hindi, J. Li et al., “Circulating urokinase receptor
as a cause of focal segmental glomerulosclerosis,” Nature
Medicine, vol. 17, no. 8, pp. 952–960, 2011.
[30] N. Alachkar, C. Wei, L. J. Arend et al., “Podocyte eﬀacement
closely links to suPAR levels at time of posttransplantation
focal segmental glomerulosclerosis occurrence and improves
with therapy,” Transplantation, vol. 96, no. 7, pp. 649–
656, 2013.
[31] R. J. Maas, J. F. Wetzels, and J. K. Deegens, “Serum-soluble
urokinase receptor concentration in primary FSGS,” Kidney
International, vol. 81, no. 10, pp. 1043-1044, 2012.
[32] Y. Harita, K. Ishizuka, A. Tanego et al., “Decreased glomerular
ﬁltration as the primary factor of elevated circulating suPAR
levels in focal segmental glomerulosclerosis,” Pediatric
Nephrology, vol. 29, no. 9, pp. 1553–1560, 2014.
[33] C. Musetti, M. Quaglia, T. Cena et al., “Circulating suPAR
levels are aﬀected by glomerular ﬁltration rate and proteinuria
in primary and secondary glomerulonephritis,” Journal of
Nephrology, vol. 28, no. 3, pp. 299–305, 2015.
[34] Y. Taniguchi, Y. Shimamura, T. Horino, S. Fujimoto, and
Y. Terada, “Serum levels of soluble urokinase plasmino-
gen activator receptor in Japanese patients with chronic
kidney disease,” Kidney International, vol. 86, no. 1,
pp. 209-210, 2014.
[35] J. Eugen-Olsen, O. Andersen, A. Linneberg et al., “Circulating
soluble urokinase plasminogen activator receptor predicts
cancer, cardiovascular disease, diabetes and mortality in the
general population,” Journal of Internal Medicine, vol. 268,
no. 3, pp. 296–308, 2010.
[36] K. Donadello, S. Scolletta, C. Covajes, and J. L. Vincent,
“suPAR as a prognostic biomarker in sepsis,” BMC Medicine,
vol. 10, no. 1, p. 2, 2012.
[37] T. H. Haupt, J. Petersen, G. Ellekilde et al., “Plasma suPAR
levels are associated with mortality, admission time, and
Charlson Comorbidity Index in the acutely admitted medical
patient: a prospective observational study,” Critical Care,
vol. 16, no. 4, article R130, 2012.
[38] H. Trachtman, C. Wei, and J. Reiser, “Circulating factor in
FSGS: a black sheep in the suPAR family?,” Pediatric Nephrol-
ogy, vol. 28, no. 7, pp. 1151-1152, 2013.
[39] D. Schlondorﬀ, “Are serum suPAR determinations by current
ELISAmethodology reliable diagnostic biomarkers for FSGS?,”
Kidney International, vol. 85, no. 3, pp. 499–501, 2014.
[40] J. A. Jeﬀerson and C. E. Alpers, “Glomerular disease: ‘suPAR’-
exciting times for FSGS,” Nature Reviews Nephrology, vol. 9,
no. 3, pp. 127-128, 2013.
[41] T. H. Yoo, C. E. Pedigo, J. Guzman et al., “Sphingomyelinase-
like phosphodiesterase 3b expression levels determine podo-
cyte injury phenotypes in glomerular disease,” Journal of the
American Society of Nephrology, vol. 26, no. 1, pp. 133–
147, 2015.
[42] M. Persson, G. Engström, H. Björkbacka, and B. Hedblad,
“Soluble urokinase plasminogen activator receptor in plasma
is associated with incidence of CVD. Results from the Malmö
Diet and Cancer Study,” Atherosclerosis, vol. 220, no. 2,
pp. 502–505, 2012.
[43] A. E. Schutte, A. Myburgh, M. H. Olsen, J. Eugen-Olsen,
and R. Schutte, “Exploring soluble urokinase plasminogen
activator receptor and its relationship with arterial stiﬀness
in a bi-ethnic population: the SAfrEIC-study,” Thrombosis
Research, vol. 130, no. 2, pp. 273–277, 2012.
[44] H. Trachtman and J. Reiser, “suPAR is the circulating factor in
some but not all FSGS,” Nature Reviews Nephrology, vol. 10,
no. 10, p. 610, 2014.
11Journal of Immunology Research
Stem Cells 
International
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
MEDIATORS
INFLAMMATION
of
Endocrinology
International Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Disease Markers
Hindawi
www.hindawi.com Volume 2018
BioMed 
Research International
Oncology
Journal of
Hindawi
www.hindawi.com Volume 2013
Hindawi
www.hindawi.com Volume 2018
Oxidative Medicine and 
Cellular Longevity
Hindawi
www.hindawi.com Volume 2018
PPAR Research
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013www.hindawi.com
The Scientific 
World Journal
8
Immunology Research
Hindawi
www.hindawi.com Volume 2018
Journal of
Obesity
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
 Computational and  
Mathematical Methods 
in Medicine
Hindawi
www.hindawi.com Volume 2018
Behavioural 
Neurology
Ophthalmology
Journal of
Hindawi
www.hindawi.com Volume 2018
Diabetes Research
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Research and Treatment
AIDS
Hindawi
www.hindawi.com Volume 2018
Gastroenterology 
Research and Practice
Hindawi
www.hindawi.com Volume 2018
Parkinson’s 
Disease
Evidence-Based 
Complementary and
Alternative Medicine
Volume 2018
Hindawi
www.hindawi.com
Submit your manuscripts at
www.hindawi.com
